Israel’s MediWound (see here previously) announced positive data from its Phase I/II study of MW005 for non-surgical treatment of Basal Cell Carcinoma (BCC) – a form of slow-growing skin cancer. MW005 is safe, well-tolerated and completely cleared the BCC lesions.
Treating Basal Cell Carcinoma
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.